| Withdrawn | The Sequestration of Holistic Stress Management Techniques for Adults NCT06098755 | Goddess Zena I. Jones | N/A |
| Recruiting | A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Su NCT06144749 | Hillhurst Biopharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Socio-ecological Approach for Improving Self-management in Adolescents With SCD NCT06290401 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Recruiting | A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease NCT06481306 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Unknown | SMILES: Study of Montelukast in Sickle Cell Disease NCT04351698 | Great Ormond Street Hospital for Children NHS Foundation Trust | Phase 2 / Phase 3 |
| Terminated | Siplizumab for Sickle Cell Disease Transplant NCT06078696 | Columbia University | Phase 1 / Phase 2 |
| Completed | Hydroxyurea and EPO in Sickle Cell Disease NCT05451940 | Julia Xu | Phase 1 / Phase 2 |
| Active Not Recruiting | Telemedicine for Children With Sickle Cell Disease NCT05087303 | Indiana University | N/A |
| Completed | A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy NCT03926819 | Hillhurst Biopharmaceuticals, Inc. | Phase 1 |
| Recruiting | European Rare Blood Disorders Platform (ENROL) NCT06250595 | Hospital Universitari Vall d'Hebron Research Institute | — |
| Recruiting | Metabolic and Hemodynamic Reserve in Pediatric SCA NCT04406818 | Washington University School of Medicine | N/A |
| Completed | Folic Acid Supplementation in Children With Sickle Cell Disease NCT04011345 | University of British Columbia | N/A |
| Completed | Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease NCT04584528 | Duke University | N/A |
| Completed | Daily Vitamin D for Sickle-cell Respiratory Complications NCT04170348 | Columbia University | Phase 2 |
| Completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunt NCT04536792 | Agios Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Desmopressin for Bedwetting in Children With SCD NCT04420585 | Montefiore Medical Center | Phase 4 |
| Terminated | CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease NCT04091737 | CSL Behring | Phase 1 |
| Completed | To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With NCT04134299 | Axcella Health, Inc | N/A |
| Completed | Specifying Interventions From the Sickle Cell Disease Implementation Consortium (SCDIC) NCT03380351 | Washington University School of Medicine | — |
| Active Not Recruiting | A Blood Stem Cell Transplant for Sickle Cell Disease NCT03249831 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Epidemiology of Silent and Overt Strokes in Sickle Cell Disease NCT03376893 | Vanderbilt University Medical Center | — |
| Unknown | STRIDE Biorepository NCT02843347 | Emory University | — |
| Terminated | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study NCT03733249 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis NCT03062501 | Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti | Phase 2 |
| Completed | Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis NCT02411708 | Prolong Pharmaceuticals | Phase 2 |
| Completed | SCD-PROMIS: A Software Platform to Enhance Self-efficacy and Patient-provider Engagement for Patients With Sic NCT03006718 | Julia Finkel | N/A |
| Completed | A Self-Management Intervention for Youth With Sickle Cell Disease and Their Families: Phase I NCT03069430 | Medical University of South Carolina | — |
| Completed | Transfusion Treatment in Patients With SCD NCT03397017 | Società Italiana Talassemie ed Emoglobinopatie | — |
| Completed | A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients NCT02672540 | Prolong Pharmaceuticals | Phase 2 |
| Unknown | tDCS Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Diseas NCT02813629 | Faculdade Adventista da Bahia | Phase 2 |
| Completed | Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell NCT02561312 | Chattanooga-Hamilton County Hospital Authority | — |
| Terminated | Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease NCT02636387 | Montefiore Medical Center | — |
| Completed | Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subject NCT02187003 | Biossil Inc. | Phase 3 |
| Completed | A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects NCT02497924 | Global Blood Therapeutics | Phase 1 |
| Terminated | Preventing Sickle Cell Kidney Disease NCT02373241 | University of Alabama at Birmingham | Phase 2 |
| Completed | MBSR for Pain Catastrophizing in SCD NCT02394587 | Duke University | N/A |
| Active Not Recruiting | Therapeutic Response Evaluation and Adherence Trial (TREAT) NCT02286154 | Children's Hospital Medical Center, Cincinnati | N/A |
| Completed | Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Dis NCT02857023 | Steven J. Hardy | N/A |
| Terminated | Gene Transfer for Patients With Sickle Cell Disease NCT02186418 | Children's Hospital Medical Center, Cincinnati | Phase 1 / Phase 2 |
| Terminated | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant NCT02065869 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Withdrawn | Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis NCT01925001 | Sangart | Phase 2 |
| Completed | Systematic Psychological and Medical Care for Children With SCD NCT02022891 | Fondation Ophtalmologique Adolphe de Rothschild | — |
| Completed | Carbon Monoxide Levels and Sickle Cell Disease Severity NCT01547793 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Safety Study of MP4CO in Adult Sickle Cell Patients NCT01356485 | Sangart | Phase 1 |
| Completed | Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis NCT01482091 | Montefiore Medical Center | Phase 4 |
| Withdrawn | Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies NCT01419704 | Talaris Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults NCT01178099 | Eli Lilly and Company | Phase 1 |
| Completed | Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease NCT01054768 | UCSF Benioff Children's Hospital Oakland | Phase 2 |
| Terminated | Clinical Importance of Treating Iron Overload in Sickle Cell Disease NCT00981370 | Children's Hospital Los Angeles | Phase 3 |
| Terminated | Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases NCT00840567 | Washington University School of Medicine | N/A |
| Completed | Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study) NCT00890396 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Parent Educational Program for Children With Sickle Cell Disease NCT00860782 | University of Miami | N/A |
| Unknown | Far Infrared Radiation for Sickle Cell Pain Management NCT00599482 | GAAD Medical Research Institute Inc. | Phase 1 |
| Terminated | Establishing a Repository of Blood and DNA Samples From People With Sickle Cell Disease (Comprehensive Sickle NCT00528203 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sick NCT01522547 | Celgene | Phase 1 |
| Completed | Role of Placenta Growth Factor in Sickle Acute Chest Syndrome NCT00448370 | Children's Hospital Medical Center, Cincinnati | — |
| Completed | Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease NCT00600665 | University of Illinois at Chicago | N/A |
| Terminated | Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease NCT00530270 | Children's Hospital Medical Center, Cincinnati | Phase 3 |
| Terminated | Stroke With Transfusions Changing to Hydroxyurea NCT00122980 | St. Jude Children's Research Hospital | Phase 3 |
| Completed | MAST - Magnesium for Sickle Cell Acute Crisis in Children NCT00313963 | The Hospital for Sick Children | Phase 3 |
| Completed | Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport NCT00246077 | Children's Mercy Hospital Kansas City | — |
| Completed | Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence NCT00300235 | University of Texas Southwestern Medical Center | — |
| Withdrawn | Dipyridamole/Magnesium To Improve Sickle Cell Hydration NCT00276146 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Terminated | Establishing a Database of People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Da NCT00529061 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Terminated | Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease NCT00115336 | Children's Hospital Medical Center, Cincinnati | Phase 4 |
| Completed | Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease NCT00528801 | UCSF Benioff Children's Hospital Oakland | — |
| Completed | Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease - Pilot Intervention S NCT00850018 | UCSF Benioff Children's Hospital Oakland | Phase 1 |
| Completed | Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease NCT00143572 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises NCT00094887 | Mallinckrodt | Phase 2 |
| Completed | Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II NCT00037388 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Effectiveness of Arginine as a Treatment for Sickle Cell Anemia NCT00513617 | UCSF Benioff Children's Hospital Oakland | Phase 2 |
| Terminated | Trial of Oral Glutamine in Patients With Sickle Cell Anemia NCT00131508 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions NCT00067080 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG NCT00059293 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Pain in Sickle Cell Epidemiologic Study NCT00035763 | Virginia Commonwealth University | — |
| Terminated | Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia NCT00034528 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients NCT00029731 | UCSF Benioff Children's Hospital Oakland | Phase 2 |
| Completed | Induction of Stable Chimerism for Sickle Cell Anemia NCT00029393 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia NCT00006400 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
| Completed | Stroke Prevention in Sickle Cell Anemia (STOP 2) NCT00006182 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
| Completed | Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia NCT00029380 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Hemostasis in Sickle Cell Disease--Infancy to Adulthood NCT00005703 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Stroke Prevention in Sickle Cell Anemia (STOP 1) NCT00000592 | Augusta University | Phase 3 |
| Completed | Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG) NCT00000602 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Prevention of Cerebral Infarction in Sickle Cell Anemia - Comprehensive Sickle Cell Center NCT00005327 | University of Southern California | — |
| Completed | Neuropsychological Studies of Children With Sickle Cell NCT00005438 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) NCT00000586 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
| Completed | Indices of Severity and Prognosis for Sickle Cell Disease NCT00005467 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease NCT00005300 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Cerebrovascular Involvement in Sickle Cell Disease - Comprehensive Sickle Cell Center NCT00005326 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Penicillin Prophylaxis in Sickle Cell Disease (PROPS) NCT00000585 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
| Completed | Cooperative Study of The Clinical Course of Sickle Cell Disease NCT00005277 | National Heart, Lung, and Blood Institute (NHLBI) | — |